155 related articles for article (PubMed ID: 38156991)
1. Highly purified charge variants of a proposed biosimilar to Omalizumab: impact on in vitro potency and stability under thermal stress.
Gupta T; Seshadri S
Bioprocess Biosyst Eng; 2024 Jan; 47(1):57-64. PubMed ID: 38156991
[TBL] [Abstract][Full Text] [Related]
2. Charge variants of proposed biosimilar to Omalizumab: Isolation, purification and analysis by HPLC methods.
Gupta T; Seshadri S
Ann Pharm Fr; 2024 Jan; 82(1):64-71. PubMed ID: 37708991
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
Joshi S; Rathore AS
BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
[TBL] [Abstract][Full Text] [Related]
4. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2022 Jun; 77():1-15. PubMed ID: 35667958
[TBL] [Abstract][Full Text] [Related]
5. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
[TBL] [Abstract][Full Text] [Related]
6. Randomized Comparative Clinical Study of First Global Omalizumab Biosimilar with Innovator Product in Moderate to Severe Persistent Asthma.
Apsangikar P; Ghadge P; Naik M; Nair S
J Assoc Physicians India; 2020 Dec; 68(12):61-65. PubMed ID: 33247645
[TBL] [Abstract][Full Text] [Related]
7. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.
Nupur N; Chhabra N; Dash R; Rathore AS
MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314
[TBL] [Abstract][Full Text] [Related]
8. LC-MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity.
Singh SK; Kumar D; Malani H; Rathore AS
Sci Rep; 2021 Jan; 11(1):2487. PubMed ID: 33514790
[TBL] [Abstract][Full Text] [Related]
9. [Structural characterization and analysis of Omalizumab and its biosimilar CMAB007 by LC-MS].
Xu J; Zhang D; Wang H; Guo H
Sheng Wu Gong Cheng Xue Bao; 2016 Apr; 32(4):497-506. PubMed ID: 28853271
[TBL] [Abstract][Full Text] [Related]
10. National Control Laboratory Assessment of Quality of Rituximab Biosimilars in India.
Mishra NN; Sharma A; Shalini S; Sharma S; Jain P; Sharma RK; Chander H; Prasad JP; Anvikar AR; Chand S
Monoclon Antib Immunodiagn Immunother; 2022 Oct; 41(5):260-274. PubMed ID: 36306517
[TBL] [Abstract][Full Text] [Related]
11. Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products.
Tan Q; Guo Q; Fang C; Wang C; Li B; Wang H; Li J; Guo Y
MAbs; 2012; 4(6):761-74. PubMed ID: 23032066
[TBL] [Abstract][Full Text] [Related]
12. Characterization and pre-clinical assessment of a proposed biosimilar to its originator Omalizumab.
Wang Y; Zheng C; Zhuang C; Fu Q; Zhang B; Bian Y; Qi N; Zhu J
Eur J Pharm Sci; 2022 Nov; 178():106292. PubMed ID: 36089232
[TBL] [Abstract][Full Text] [Related]
13. Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin
Gurel B; Berksoz M; Capkin E; Parlar A; Pala MC; Ozkan A; Capan Y; Daglikoca DE; Yuce M
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015197
[TBL] [Abstract][Full Text] [Related]
14. Charge variant analysis of proposed biosimilar to Trastuzumab.
Dakshinamurthy P; Mukunda P; Prasad Kodaganti B; Shenoy BR; Natarajan B; Maliwalave A; Halan V; Murugesan S; Maity S
Biologicals; 2017 Mar; 46():46-56. PubMed ID: 28087106
[TBL] [Abstract][Full Text] [Related]
15. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2021 Sep; 73():41-56. PubMed ID: 34593306
[TBL] [Abstract][Full Text] [Related]
16. Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat.
Zhao YY; Wang N; Liu WH; Tao WJ; Liu LL; Shen ZD
PLoS One; 2016; 11(3):e0151874. PubMed ID: 26987122
[TBL] [Abstract][Full Text] [Related]
17. From bioequivalence to biosimilars: How much do regulators dare?
Weise M
Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
[TBL] [Abstract][Full Text] [Related]
18. Combined analytical assays for the characterization of drugs binding to human IgE: Applicability to omalizumab-bearing biosimilar candidates assessment.
Urbano A; Plaza J; Picado C; de Mora F
Biomed Pharmacother; 2023 Dec; 169():115848. PubMed ID: 37976893
[TBL] [Abstract][Full Text] [Related]
19. Development of biosimilars.
Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
[TBL] [Abstract][Full Text] [Related]
20. Cation exchange chromatography on a monodisperse 3 µm particle enables extensive analytical similarity assessment of biosimilars.
Füssl F; Millán-Martín S; Bones J; Carillo S
J Pharm Biomed Anal; 2023 Sep; 234():115534. PubMed ID: 37343453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
